GURGAON, India — Ranbaxy Labs recently marked the 20th anniversary of its operations in Russia, the India-based generic drug company announced.
Ranbaxy established its operations in the Russian market in 1993 with the launch of its key brand, Cifran, and since then, it has grown to command a market share of 15.4% in the country, according to IMS Health.
Today, the company operates in 56 regions of Russia, with 51 drugs registered and 72 SKUs commercialized. Its range of products include drugs for infections, pain, cardiovascular disease, diabetes, central nervous system disorders, skin diseases and so forth.
"Ranbaxy was one of the first pharmaceutical companies from India to set up operations in Russia," Ranbaxy CEO Arun Sawhney said. "We have been providing high-quality, affordable generic medicines to the citizens of Russia for the last two decades, thereby supporting the government to bring down healthcare costs."